Navigation Links
DO-HEALTH a multi-center clinical trial on healthy ageing achieves first milestone
Date:9/9/2013

Nyon, Switzerland (September 9, 2013) Europe's largest healthy ageing study DO-HEALTH which aims to provide evidence for the safety of three simple preventive interventions: vitamin D, omega-3 fatty acids and a simple home exercise programme, has recruited 532 of its target 2,000 seniors. In Europe, the number of seniors aged 70 and over will increase by 40 per cent in the next 20 years, and those aged 80 and above will more than double. If action to ensure people age healthily is not taken, not only will it impact their quality of life but it will result in a huge economic burden on health systems in the future.

This is the first large European multi-centre clinical trial which seeks to provide evidence for effective, affordable, and well-tolerated strategies that prevent or delay chronic disease at older age and prolong healthy life expectancy. "We are pleased to announce that the DO-HEALTH study is on track and on target in achieving the 25% recruitment milestone," announced Professor Heike Bischoff-Ferrari, Director of the Centre on Aging and Mobility of Zurich University and DO-HEALTH Principal Investigator.

The seven participating DO-HEALTH study centres in Switzerland, Austria, France, Germany, Portugal and Switzerland are recruiting participants who are 70 years or older, mobile and living independently at home, to take part in the three-year study. Five of the centres are above their targets with 26 to 36% of participants already recruited.

As the European population rapidly ages, age-related chronic diseases in seniors have become a central concern. Chronic diseases prevent millions of seniors from leading longer, more active and independent lives while placing a heavy burden on health care systems and society as a whole.

Among the most promising affordable strategies to promote healthy ageing are vitamin D, marine omega-3 fatty acids and physical exercise. However, their individual and combined effects have yet to be confirmed in a large clinical trial. DO-HEALTH will investigate the impact of these simple strategies in the prevention of chronic disease at older age and will study their role in the prevention of fractures and falls, functional decline, high blood pressure, cognitive decline and pain from osteoarthritis.

International Osteoporosis Foundation CEO, Judy Stenmark stated "Chronic diseases are by far the leading cause of mortality in the world, imposing an enormous burden on patients, their families and on society as a whole. With its ageing population, Europe will have to deal with a dramatic increase in chronic diseases in the next decade therefore, studies such as DO-HEALTH are essential in helping us to better understand and control the disease burden."

She continued, "DO-HEALTH is set to make a vital contribution to the development of low-cost, universally accessible strategies in the fight against age-related chronic diseases. IOF congratulates the DO-HEALTH centres for their dedication to this important study."


'/>"/>

Contact: Charanjit K. Jagait
CJagait@iofbonehealth.org
41-229-940-102
International Osteoporosis Foundation
Source:Eurekalert

Related biology news :

1. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
2. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
3. New clinical trial explores novel noninvasive colon cancer screening test
4. Genzyme/ACMG Foundation Genetics Training Award in Clinical Biochemical Genetics announced
5. FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update
6. MedNet Solutions to Demonstrate Its Innovative Suite of eClinical Solutions at the 2012 Bio-IT World Conference & Expo
7. Clinical trial launches to see whether vitamin D helps treat multiple sclerosis
8. AAO-HNS releases updated Clinical Indicators
9. Sequencing works in clinical setting to help -- finally -- get a diagnosis
10. VolitionRX Raises Over $1 Million To Begin Clinical Trials of Blood Based Diagnostic Tests
11. Clinical trials for Alzheimers disease preventative drug to begin early 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2020)... ... July 03, 2020 , ... ... earn outstanding recognition and multiple awards for not only the products and treatments ... SoME® Skincare and Vivace® Microneedle RF. All the brands built by ABM have ...
(Date:7/1/2020)... ... July 01, 2020 , ... Cure Glioblastoma, a registered 501(c)(3) ... and aggressive adult brain cancer—announced today the appointments of its first Senior Fellows: ... supporting the organization’s initiatives and overall vision. , "Senior Fellows are more than ...
(Date:6/23/2020)... ... June 23, 2020 , ... Kemp ... announced that the company has received ISO9001:2015 certification for the development and ... industries. The decision to pursue ISO9001 accreditation demonstrates Kemp’s commitment to a ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... and SOMERSET, N.J (PRWEB) , ... July 29, ... ... genome editing company, and Catalent, the leading global provider of advanced delivery technologies, ... health products, today announced that they have entered into a strategic partnership whereby ...
(Date:7/22/2020)... ... ... Join experts from Reed Tech , Gary Saner, Sr. Manager, Information ... live webinar on Thursday, August 13, 2020 at 11am EDT (4pm BST/UK). ... Specifically, for medical devices, the NMPA has departments dealing with medical device registration (pre-market ...
(Date:7/18/2020)... ... , ... dicentra , a leading Contract Research Organization ... pleased to announce that Charles Galea has joined its clinical trials division as ... accomplished and results-driven sales executive with over 10 years of expertise in business ...
(Date:7/10/2020)... (PRWEB) , ... July 09, 2020 , ... ... to cell therapy, today announced the hiring of Allen R. Nissenson, M.D., F.A.C.P., ... and oversee the clinical development of Sentien’s lead product, SBI-101. Dr. Nissenson ...
Breaking Biology Technology: